Scope
Description
Provision of Licensed Medical Retinal Vascular Anti Veg-F and Intravitreal Corticosteroid medicines used in medical retinal vascular services for the NHS in England. To include but not limited to aflibercept, bevacizumab, brolucizumab, intravitreal dexamethasone, intravitreal fluocinolone, faricimab and ranibizumab used in the treatment of; • neovascular (wet) age-related macular degeneration (AMD) • visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) • proliferative diabetic retinopathy (PDR) • visual impairment due to diabetic macular oedema (DME) • visual impairment due to diabetic macular oedema (DME) who are pseudophakic or who are considered insufficiently responsive to, or unsuitable for non-corticosteroid therapy • vision impairment associated with chronic diabetic macular oedema, (DME) • visual impairment due to myopic choroidal neovascularisation (myopic CNV) • retinopathy of prematurity (ROP) with zone I (stage 1+, 2+, 3 or 3+), zone II (stage 2+ or 3+) or AP-ROP (aggressive posterior ROP) disease • inflammation of the posterior segment of the eye presenting as non-infectious uveitis • prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye
Commercial tool
Establishes a framework
Total value (estimated)
- £1,520,432,295 excluding VAT
- £1,824,518,754 including VAT
Above the relevant threshold
Contract dates (estimated)
- 1 December 2025 to 31 May 2027
- Possible extension to 31 May 2029
- 3 years, 6 months
Description of possible extension:
Option or options to extend (at the discretion of the Authority) up to maximum of 24 months.
Main procurement category
Goods
CPV classifications
- 33600000 - Pharmaceutical products
- 33690000 - Various medicinal products
Contract locations
- UK - United Kingdom
Lot constraints
Maximum number of lots a supplier can bid for: 1
Maximum number of lots a supplier can be awarded: 1
Description of how multiple lots may be awarded:
There is no maximum number of Lots that can be awarded in Lot 1 - In Lot 2 there are 4 sub-lots - suppliers can be awarded only one sub-lot (subject to the number of bidders - see tender pack for further details)
Lot 1. CM/PHS/25/5728/01 - National Framework for Medical Retinal Vascular Treatments:
Description
CM/PHS/25/5728/01 - National Framework for Medical Retinal Vascular Treatments: 7NAT (National)
Lot value (estimated)
- £709,529,158 excluding VAT
- £851,434,989 including VAT
Framework lot values may be shared with other lots
Same for all lots
CPV classifications, contract locations and contract dates are shown in the Scope section, because they are the same for all lots.
Lot 2. CM/PHS/25/5728/02 - Regional Framework for Medical Retinal Vascular Treatments a
Description
CM/PHS/25/5728/02 - Regional Framework for Medical Retinal Vascular Treatments aflibercept 2mg
Lot value (estimated)
- £810,903,137 excluding VAT
- £973,083,765 including VAT
Framework lot values may be shared with other lots
Same for all lots
CPV classifications, contract locations and contract dates are shown in the Scope section, because they are the same for all lots.
Framework
Maximum number of suppliers
Unlimited
Maximum percentage fee charged to suppliers
0%
Further information about fees
N/A
Framework operation description
Please refer to the ITO Documents for the Operation Description
Award method when using the framework
Without competition
Contracting authorities that may use the framework
Please refer to Document No. 09 in the ITO Documents for the list of Purchasing Points
Contracting authority location restrictions
- UKH - East of England
- UKG - West Midlands (England)
- UKE - Yorkshire and the Humber
- UKI - London
- UKC - North East (England)
- UKD - North West (England)
- UKF - East Midlands (England)
Participation
Particular suitability
Lot 1. CM/PHS/25/5728/01 - National Framework for Medical Retinal Vascular Treatments:
Lot 2. CM/PHS/25/5728/02 - Regional Framework for Medical Retinal Vascular Treatments a
Small and medium-sized enterprises (SME)
Submission
Enquiry deadline
7 July 2025, 1:00pm
Tender submission deadline
14 July 2025, 1:00pm
Submission address and any special instructions
The procurement documents are available for unrestricted and full direct access, free of charge at https://health-family.force.com/s/Welcome Additional info obtained from the abovementioned address Tenders must be submitted to the abovementioned address.
Tenders may be submitted electronically
Yes
Languages that may be used for submission
English
Award decision date (estimated)
31 July 2025
Award criteria
| Name | Type |
|---|---|
| Price | Price |
| Quality | Quality |
Weighting description
Please see ITO Pack.
Other information
Applicable trade agreements
- Government Procurement Agreement (GPA)
Conflicts assessment prepared/revised
Yes
Procedure
Procedure type
Open procedure
Contracting authority
NHS England
- Public Procurement Organisation Number: PDPT-3135-BWWY
Wellington House, 133-135 Waterloo Rd
London
SE1 8UG
United Kingdom
Region: UKI45 - Lambeth
Organisation type: Public authority - central government